Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data ...
NCI director Ned Sharpless as MD and Andrew Witty as chairman, while raising a $100M second opportunities fund.
Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
Breye Therapeutics raised €67.5M Series A; Aptadir raised €40M seed; Ascletis' ASC50 shows psoriasis results; Invivyd touts ...
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
Oura delays IPO citing market uncertainty despite $1.2B revenue and strong demand. Anthropic, OpenAI, Holtec, and Bamboo ...
Bio raises $48M Series A led by UPMC Enterprises & Ziff Capital to target Th17 cells via CD161+ antibody & CAD mRNA platforms ...
Fresenius Kabi will sell biosimilars for Humira, Stelara & Actemra directly to employers via Eversana's Waltz Health, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results